Explore this article's sources with AI
Follow PeptideMethods on Google
GLP-1 Weight Loss and Endocrine Therapy
A 269-patient retrospective cohort reports GLP-1-associated weight change during adjuvant endocrine therapy for breast cancer.
Why we wrote this. This report needs a clear boundary between observed weight change in a complex cohort and conclusions about cancer or individual treatment.
In this article (5 sections)
A retrospective cohort study reports weight outcomes among breast cancer patients who used a GLP-1 receptor agonist while receiving adjuvant endocrine therapy. The authors found mean one-year weight change of minus 4.5% in the cohort. This is an observational result from one academic center. It does not establish a causal effect, a cancer outcome, or a personal treatment recommendation[1].
What the study examined
The paper concerns patients with breast cancer receiving adjuvant endocrine therapy and concurrent GLP-1 receptor agonist treatment. Researchers used electronic medication-reconciliation lists and pharmacy dispensing reports at a single academic center. Participants had started GLP-1 therapy during the study period and received both treatments for at least one year[1]. The DOI record identifies the article as a retrospective cohort analysis published in Breast Cancer Research and Treatment[2].
The primary outcome was percentage weight change from GLP-1 initiation to about 12 months. The abstract reports a mean one-year change of minus 4.5%, equivalent to minus 3.9 kilograms, with a 95% confidence interval from minus 6.0% to minus 3.0%. A cohort average is not a forecast for any one patient[1].
The authors compared that observed change with figures reported in postmenopausal subgroups of GLP-1 randomized trials. Their wording is important: this is not a randomized head-to-head trial of endocrine therapy effects. The cohort had its own clinical characteristics, treatment histories, and record-based inclusion process. Our semaglutide evidence page provides separate context on trial evidence.
Results reported by the authors
In the study, 21.3% of participants achieved at least 10% weight loss and 10.4% achieved at least 15% weight loss. Weight change differed by GLP-1 agent in the authors' analysis. The abstract reports mean changes of minus 5.8% for semaglutide, minus 4.7% for tirzepatide, and plus 0.1% for dulaglutide. Those are subgroup observations, not proof that one medicine should be selected for a person receiving cancer care[1].
The report also notes that 70.6% of the cohort had type 2 diabetes. In a t-test, diabetes status was not significantly associated with weight loss, while the proportion reaching the higher weight-loss threshold was numerically different between groups. Those observations need careful interpretation because they arise from a retrospective cohort rather than a trial assigned to answer that question[1].
Why study design matters
A retrospective cohort can document outcomes seen in a defined care setting. It cannot fully control who received a medicine, why treatment was chosen, what else changed during the year, or which unmeasured factors influenced weight. The paper itself calls for prospective trials. That is not a minor caveat. It is the boundary between an observed association and a conclusion about treatment effects[1].
Endocrine therapy, cancer history, metabolic illness, and concurrent medicines create a clinically complex setting. This analysis does not show that GLP-1 treatment improves cancer outcomes, reduces recurrence, or is suitable for all breast cancer patients. It reports weight outcomes in its cohort. Readers should keep that narrow question separate from the broader oncology decisions discussed with a treating team.
How to use this information safely
The study can help readers identify a research gap: weight change observed during concurrent endocrine therapy may differ from weight change reported in other populations. It does not provide a protocol for use, a dosing plan, or a substitute for oncology and prescribing advice. It also cannot determine the safety of combining a GLP-1 medicine with every endocrine regimen[1].
The distinction matters because a medicine can be evaluated differently in a controlled trial and in routine care. In records-based research, treatment exposure is identified after clinical decisions have already occurred. The investigators can adjust only for information available to their analysis. Missing variables, incomplete records, or different follow-up patterns can influence the result. None of that makes the report unhelpful. It tells readers what type of question it can answer.
Weight is also one outcome among many in cancer care. A numerical change may be meaningful to a patient, yet it does not independently establish a favorable overall balance of benefits and harms. That balance requires clinical context. Our semaglutide evidence page, safety page, and regulation page cover separate aspects of the evidence.
The paper is useful, but its scope is narrow. A single-center retrospective analysis can illuminate an important clinical experience while leaving major questions unresolved, particularly when its patients, record capture, treatment decisions, and follow-up differ from those in another care system. That is why prospective work remains necessary before the observation can be generalized. The semaglutide evidence hub offers separate trial context.
If someone is considering a GLP-1 medicine during breast cancer treatment, the relevant discussion is individual and multidisciplinary. A clinician can review the cancer plan, other medicines, symptoms, nutritional needs, and medical history. That conversation cannot be replaced by an average from a retrospective chart review. See our semaglutide safety context, trial evidence context, medicine-status context, and semaglutide overview for general evidence context, not personal care instructions.
What the report supports
This 269-patient study found statistically significant but more modest average weight loss than the trial figures used for comparison by its authors. It supports further prospective research in this specific clinical setting. It does not establish an oncologic benefit or tell an individual what treatment to take. This article is educational and is not medical advice. People receiving cancer treatment should discuss medication questions with their oncology and prescribing clinicians.
Frequently asked
What did this study find?
The cohort's mean one-year percentage weight change was minus 4.5% during concurrent GLP-1 receptor agonist and endocrine therapy.
Was this a randomized trial?
No. It was a retrospective cohort analysis at one academic center, so it can report observed associations but cannot establish causal effects.
Does this show GLP-1 medicines improve breast cancer outcomes?
No. The reported outcome was weight change. The abstract does not establish an effect on recurrence, survival, or other cancer outcomes.
Should someone change treatment after reading it?
No. This is educational research coverage, not medical advice. Decisions during cancer treatment belong with the treating oncology and prescribing teams.
Sources
No revisions yet. First published .